Overview

Trial of Magrolimab (Hu5F9-G4) in Combination With Avelumab in Solid Tumor Participants and Checkpoint-Inhibitor-Naive Ovarian Cancer Participants Who Progress Within 6 Months of Prior Platinum Chemotherapy

Status:
Completed

Trial end date:
2020-12-03

Target enrollment:

Participant gender:

Summary

The primary objectives of this study are to investigate the safety and tolerability of magrolimab in combination with avelumab in participants with advanced solid tumors and to confirm the safety and tolerability of this combination and evaluate the anti-tumor activity based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 (Eisenhauer 2009) in participants with checkpoint inhibitor-naive ovarian cancer, fallopian tube cancer, and primary peritoneal carcinoma who have previously progressed within 1-6 months of receiving platinum chemotherapy.

Phase:

Phase 1

Details

Lead Sponsor:

Forty Seven, Inc.
Gilead Sciences

Collaborators:

Merck KGaA
Merck KGaA, Darmstadt, Germany

Treatments:

Antibodies, Monoclonal
Avelumab
Magrolimab